At Nanostics our focus is on the development of novel and non-invasive diagnostic tests to bring clarity to healthcare decisions.

Our core technology is in development to be able to diagnose disease from a simple blood test by combining a highly sensitive extracellular vesicle detection platform with advanced machine learning algorithms.

The Challenge:

Each drop of blood carries billions of messages with critical information.


This wealth of information is transmitted throughout our bodies via the bloodstream using a complex extracellular vesicle messaging system.


It is a monumental challenge to detect and decipher these messages to better diagnose and manage the treatment of disease.

Our Solution:

Our core technology can read and decipher information from millions of particles in a single drop of blood with unprecedented accuracy.


Our non-invasive and cost-effective technology combines advanced microflow cytometry with sophisticated machine learning algorithms and is currently in developmental trials to provide more timely and accurate information that can be used to better understand disease.

Our novel technology is applicable to a wide range of diseases, including prostate, brain,
pancreatic and blood cancers
as well as cardiovascular and neuro-degenerative diseases.

Learn More

Our lead product currently in development, ClarityDx Prostate, is designed to be a highly accurate test to diagnose clinically significant prostate cancer and improve prostate healthcare decisions.

Please note: this product is under development and so currently has not received regulatory approval or clearance in any markets.

Learn More

Our success would not be possible without the support of our many Canadian and internationalcollaborators, funders and partners.